Advertisement

Light/Heavy Chain Deposition Disease as a Systemic Disorder

  • Guillermo A. HerreraEmail author
  • Elba A. Turbat-Herrera
Part of the Current Clinical Pathology book series (CCPATH)

Abstract

Light/heavy chain deposition disease (LHCDD) is a disorder with predominantly renal manifestations, though sometimes associated with systemic involvement. While the recognition of LHCDD in the kidney by pathologists has increased considerably in the last decade, that is not the case when other organs are involved. If the patient has already a diagnosis of LCHDD, then the index of suspicion is raised and recognition of extrarenal manifestations is markedly improved. This chapter highlights diagnostic criteria, challenges, and pitfalls in the differential diagnosis of LHCDD in non-renal sites. It also discusses pathogenic mechanisms associated with organ pathology.

Keywords

Light chains Light chain deposition disease Heavy chains Heavy chain deposition disease Immunofluorescence Immunohistochemistry Electron microscopy Immunogold labeling Pathology Pathogenesis 

References

  1. 1.
    Fernand J-P, Brouet J-C. Heavy-chain diseases. Hematol Oncol Clin N Am. 1999;13:1281–94.CrossRefGoogle Scholar
  2. 2.
    Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1:1342–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Ronco PM, Alyanakian M-A, Mougenot B, et al. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol. 2001;12:1558–65.PubMedGoogle Scholar
  4. 4.
    Kambham N, Markowitz GS, Appel GB, et al. Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis. 1999;33:954–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition diseases. Hematol Oncol Clin North Am. 1999;13:1235–48.CrossRefPubMedGoogle Scholar
  6. 6.
    Lin J, Markowitz GS, Valeri AM, Kambham N, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12:1482–92.PubMedGoogle Scholar
  7. 7.
    Herrera GA, Joseph L, Gu X, et al. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasias. Arch Pathol Lab Med. 2004;128:875–9.PubMedGoogle Scholar
  8. 8.
    Nasr SH, Valeri AM, Cornell LD, Fidler ME, et al. Renal monoclonal immunoglobulin deposition disease: A report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7:231–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Ivanyi B. Frequency of light chain nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med. 1990;114:986–7.PubMedGoogle Scholar
  10. 10.
    Khamlichi AA, Aucouturier P, Preud’Homme JL, Cogne M, et al. Structure of abnormal heavy chains in human heavy-chain deposition disease. Eur J Biochem. 1995;229:54–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Cogne M, Silvain C, Khamlichi AS, et al. Structurally abnormal immunoglobulins in human lymphoproliferative disorders. Blood. 1992;79:2181–95.PubMedGoogle Scholar
  12. 12.
    Preud’homme JL, Aucouturiere P, Touchard G, et al. Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations. Int J Immunopharmacol. 1994;16:425–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Khamlichi AA, Rocca A, Touchard G, et al. Role of light chain variable region in myeloma with light chain deposition disease: evidence from experimental model. Blood. 1995;86:3655–9.PubMedGoogle Scholar
  14. 14.
    Turner M. Molecules which recognize antigen. In: Roitt IM, Brostoff J, Male DK, editors. Immunology. St Louis, MO: Mosby; 1989. p. 5.1–5.11.Google Scholar
  15. 15.
    Santostefano M, Zanchelli F, Zaccaria A, et al. The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol. 2005;18:659–75.PubMedGoogle Scholar
  16. 16.
    Herrera GA. The contributions of electron microscopy to the understanding and diagnosis of plasma cell dyscrasia-related renal lesions. Med Electron Microsc. 2001;34:1–18.CrossRefPubMedGoogle Scholar
  17. 17.
    Gallo G, Picken MM, Buxbaum J, et al. Deposits in monoclonal immunoglobulin deposition disease lack amyloid P component. Mod Pathol. 1988;1:453–6.PubMedGoogle Scholar
  18. 18.
    Antonovych TT, Lin RC, Parrish E. Light chain deposits in multiple myeloma. 7th Annual Meeting of the American Society of Nephrology, 173 (Abstract #3). Lab Invest. 1974; 30: 370A.Google Scholar
  19. 19.
    Randall RE, Williamson WC, Mullinax F, et al. Manifestations of systemic light chain deposition. Am J Med. 1976;60:293–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Husby G, Blichfeld P, Brinch L, et al. Chronic arthritis and gamma heavy chain disease: coincidence or pathogenic link? Scand J Rheumatol. 1998;27:257–64.CrossRefPubMedGoogle Scholar
  21. 21.
    Husby G. Is there a pathogenetic link between gamma heavy chain disease and chronic arthritis? Curr Opin Rheumatol. 2000;12:65–70.CrossRefPubMedGoogle Scholar
  22. 22.
    Rott T, Vizjak A, Lindic J, et al. IgG heavy-chain deposition disease affecting both kidneys, skin, and skeletal muscle. Nephrol Dial Transplant. 1998;13:1825–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Aucouturier P, Khamlichi AA, Touchard G, et al. Brief report: heavy chain deposition disease. N Engl J Med. 1993;329:1389–93.CrossRefPubMedGoogle Scholar
  24. 24.
    Hendershot I, Bole D, Kearney JF. Assembly and secretion of heavy chains that do not associate post-translationally with immunoglobulin heavy chain binding protein. J Cell Biol. 1987;104:761–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Cohen JJ. Case records of the Massachusetts General Hospital. Weekly clinicopathologic exercises. Case 1–1981. N Engl J Med. 1981;304:33–43.CrossRefGoogle Scholar
  26. 26.
    Linder J, Croker BP, Vollmer RT, et al. Systemic kappa light-chain deposition. An ultrastructural study. Am J Surg Pathol. 1983;7:85–93.CrossRefPubMedGoogle Scholar
  27. 27.
    Herrera GA. Renal manifestations in plasma cell dyscrasias: an appraisal from the patients’ bedside to the research laboratory. Ann Diagn Pathol. 2000;4:174–200.CrossRefPubMedGoogle Scholar
  28. 28.
    Herrera GA. Renal lesions associated with plasma cell dyscrasias: practical approach to diagnosis, new concepts, and challenges. Arch Pathol Lab Med. 2009;133:249–67.PubMedGoogle Scholar
  29. 29.
    Ganeval D, Mignon F, Preud’homme JL, et al. Visceral deposition of monoclonal light chains and immunoglobulins: a study of renal and immunopathologic abnormalities. Adv Nephrol Necker Hosp. 1982;11:25.Google Scholar
  30. 30.
    Herrera GA, Turbat-Herrera EA, Viale G, et al. Ultrastructural immunolabeling in renal diseases: past, present and future expectations. Pathol Immunopathol Res. 1987;6:51–63.CrossRefPubMedGoogle Scholar
  31. 31.
    Girelli CM, Lodi G, Rocca F. K Light chain deposition disease of the liver. Eur J Gastroenterol Hepatol. 1998;10:429–30.CrossRefPubMedGoogle Scholar
  32. 32.
    Katz A, Zent R, Bargman JM. IgG heavy-chain deposition disease. Mod Pathol. 1994;7:874.PubMedGoogle Scholar
  33. 33.
    Droz D, Noel LH, Carnot F, et al. Liver involvement in nonamyloid light chain deposition disease. Lab Invest. 1984;50:683–9.PubMedGoogle Scholar
  34. 34.
    Ganeval D, Noel LH, Preud’homme JL, et al. Light chain deposition disease: Its relation to AL-type amyloidosis. Kidney Int. 1984;26:1–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Jego P, Paillard F, Ramée MP, Grosbois B. Congestive heart failure: revealing light chain deposition disease. Eur J Intern Med. 2000;11:101–3.CrossRefPubMedGoogle Scholar
  36. 36.
    Fabbian F, Stabellini N, Sartori S, et al. Light chain deposition disease presenting as paroxysmal atrial fibrillation: a case report. J Med Case Rep. 2007;1:187–93.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Fisher L, Korfel A, Stoltenburg-Didinger G, et al. A 19-year-old male with generalized seizures, unconsciousness and a deviation of gaze. Brain Pathol. 2006;16:185–6.CrossRefGoogle Scholar
  38. 38.
    Popovic M, Tavcar R, Glavac D, et al. Light chain deposition disease restricted to the brain: the firs case report. Hum Pathol. 2007;38:179–84.CrossRefPubMedGoogle Scholar
  39. 39.
    Kijner CH, Yousem SA. Systemic light chain deposition disease presenting as multiple pulmonary nodules. A case report and review of the literature. Am J Surg Pathol. 1988;12:401–13.CrossRefGoogle Scholar
  40. 40.
    Bhargava P, Rushin JM, Rusnok EJ, et al. Pulmonary light chain deposition disease. Report of five cases and review of the literature. Am J Surg Pathol. 2007;31:267–76.CrossRefPubMedGoogle Scholar
  41. 41.
    Chen KT. Amyloidosis presenting in the respiratory tract. Pathol Ann. 1989;24:253–73.Google Scholar
  42. 42.
    Colby T, Kos MN, Travis WD. Tumors of lower respiratory tract. Atlas of tumor pathology. Washington, DC: American Registry of Pathology; 1995. p. 495–501.Google Scholar
  43. 43.
    Colombat M, Stern M, Groussard O, et al. Pulmonary cystic disease related to light chain deposition disease. Am J Respir Crit Care Med. 2006;173:777–80.CrossRefPubMedGoogle Scholar
  44. 44.
    Morinaga S, Watanabe H, Gemma A, et al. Plasmacytoma of the lung associated with nodular deposits of immunoglobulins. Am J Surg Pathol. 1987;11:989–9995.CrossRefPubMedGoogle Scholar
  45. 45.
    Warfel K, Benson MD, Hull MT, et al. Pulmonary nodules and pleural plaques in systemic light chain deposition disease (LCDD). Lab Invest. 1987;500:84a.Google Scholar
  46. 46.
    Khoor A, Myers JL, Tazelaar HD, et al. Amyloid-like pulmonary nodules, including localized light chain deposition: clinicopathologic analysis of three cases. Am J Clin Pathol. 2004;121:200–4.CrossRefPubMedGoogle Scholar
  47. 47.
    Morigana S, Watanabe H, Gemma A, et al. Plasmacytoma of the lung with nodular deposits of immunoglobulin. Am J Surg Pathol. 1987;11:989–95.CrossRefGoogle Scholar
  48. 48.
    Piard F, Yaziji N, Jarry O, et al. Solitary plasmacytoma of the lung with light chain extracellular deposits: a case report and review of the literature. Histopathology. 1998;32:356–61.CrossRefPubMedGoogle Scholar
  49. 49.
    Stokes MB, Jagirdar J, Burchstin O, et al. Nodular pulmonary immunoglobulin light chain deposits with coexistent amyloid and non-amyloid features in an HIV-infected patient. Mod Pathol. 1997;10:1059–65.PubMedGoogle Scholar
  50. 50.
    Russell WJ, Cardelli J, Harris E, et al. Monoclonal light chain-mesangial cell interactions: early signaling events and subsequent pathologic effects. Lab Invest. 2001;81:689–703.CrossRefPubMedGoogle Scholar
  51. 51.
    Zhu L, Herrera GA, Murphy-Ullrich JE, et al. Pathogenesis of glomerulosclerosis in light chain deposition disease. Am J Pathol. 1995;147:375–85.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Keeling J, Herrera GA. An in vitro model of light chain deposition disease. Kidney Int. 2009;75:634–45.CrossRefPubMedGoogle Scholar
  53. 53.
    Teng J, Zhang PL, Russell WJ, et al. Insights into mechanisms responsible for mesangial alterations associated with fibrogenic glomerulopathic light chains. Nephron Physiol. 2003;94:28–38.CrossRefGoogle Scholar
  54. 54.
    Keeling J, Teng J, Herrera GA. AL-amyloidosis and light chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84:1322–38.CrossRefPubMedGoogle Scholar
  55. 55.
    Ronco P, Plaisier E, Aucouturier P. Monoclonal immunoglobulin light and heavy chain deposition diseases: molecular models of common diseases. In: Ronco C, editor, Herrera G, editor. Experimental models of renal diseases Pathogenesis and diagnosis contributions to nephrology. Basel: Karger; 2011. p. 220–31.Google Scholar
  56. 56.
    Trinkaus-Randall V, Walsh MT, Steeves S, et al. Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am J Pathol. 2005;106:197–208.CrossRefGoogle Scholar
  57. 57.
    Picken MM, Frangione B, Barlogie B, Luna M, Gallo G. Light chain deposition disease derived from the kappa I light chain subgroup. Biochemical characterization. Am J Pathol. 1989;134:749–54.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Rocca A, Khamlichi AA, Noël L-H, et al. Primary structure of a variable region of the VκI subgroup (ISE) in light chain deposition disease. Clin Exp Immunol. 1993;91:506–9.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Decourt C, Cogne M, Rocca A. Structural peculiarities of a truncated VκIII immunoglobulin light chain in myeloma with light chain deposition disease. Clin Exp Immunol. 1996;106:357–61.PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.
    Gu M, Wilton R, Stevens FJ. Diversity and diversification of light chains in myeloma: the specter of amyloidogenesis by proxy. In: Herrera GA, editor. The kidney in plasma cell dyscrasias, Contributions to Nephrology series. S Karger AG: Basel; 2007. p. 156–81.Google Scholar
  61. 61.
    Jacquot C, Saint-Andre JP, Touchard G, et al. Association of systemic light chain deposition disease and amyloidosis: a report of 3 patients with renal involvement. Clin Nephrol. 1985;24:93–8.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Guillermo A. Herrera
    • 1
    Email author
  • Elba A. Turbat-Herrera
    • 2
  1. 1.Department of PathologyLouisiana State University Health Sciences CenterShreveportUSA
  2. 2.Departments of Pathology and MedicineLouisiana State UniversityShreveportUSA

Personalised recommendations